“…Furthermore, it was also found that Astragaloside IV could mitigate myocardial lipotoxic injury induced by abnormal lipid metabolism in DCM rats by reducing circulating TC, TG, and high‐density lipoprotein (HDL) levels and cardiac lipid accumulation (Wang et al, 2020). Similarly, tetramethylpyrazine, a biologically active ingredient extracted from Chuanxiong rhizoma, has been proved to inhibit palmitic acid‐induced lipotoxicity in H9C2 cells by increasing the expression of genes related to fatty acid metabolism, such as p‐AKT, p‐AMPK, SIRT1, PGC‐1α, PPAR‐α, CD36, and CPT‐1b (Chen, Li, et al, 2015; Chen, Tsai, et al, 2015). Broadly speaking, most traditional Chinese medicines ameliorate DCM by inhibiting fatty acid uptake while accelerating fatty acid oxidation.…”